Advertisement

Grifols, S.A. GRFS

Set alert

Price alert · GRFS

All alert types
8.51 USD +0.41 +5.06%

At close · Nov 2

8.37 -0.14 -1.69%

After hours · Nov 2, 4:23 PM ET

Bid
8.50 × 1
Ask
8.51 × 1
8.25 Day range 8.58
6.96 52-week range 9.90
YTD
-8.98%
1 year
-9.18%
Open
8.30
Prev close
8.10
Mkt cap
5.79B
Vol
1.59M
Avg vol
535.73K
EPS
0.77
P/E
11.05
Div yield
1.31%
More statistics
Low
8.25
High
8.58
Forward P/E
6.39
Beta
1.14
Short ratio
11.06
Inst. own
57.27%
Dividend
0.11
Ex-div date
Jul 1, 2026
Earnings
Nov 2, 2026
50-d avg
7.59
200-d avg
8.00
1y target
10.37

YTD chart

Chart tools
Interval

Events in this range
  • Feb 26, 2026Earnings: 0.2891; estimate 0.29; surprise -0.31%
  • May 7, 2026Earnings: 0.1731; estimate 0.1613; surprise 7.32%
  • Jul 2, 2026Dividend: 0.10582
  • Jul 28, 2026Earnings: 0.2512; estimate 0.27; surprise -6.96%
  • Oct 26, 2026Rating: JP Morgan · Neutral → Neutral
  • Nov 2, 2026Earnings: —; estimate 0.3202; surprise —%
Signals (44)
NameDateAgo
RSI: OverboughtNov 2, 202611 hours ago
SMA: BullishOct 27, 20266 days ago
SMA: BullishOct 26, 20261 week ago
SMA: BearishOct 20, 20261 week ago
SMA: BullishOct 16, 20262 weeks ago
MACD: Buy SignalOct 2, 20261 month ago
SMA: BearishSep 10, 20261 month ago
MACD: Sell SignalAug 13, 20262 months ago
SMA: BullishJul 20, 20263 months ago
MACD: Buy SignalJul 7, 20263 months ago
MACD: Sell SignalJun 30, 20264 months ago
MACD: Buy SignalJun 26, 20264 months ago
MACD: Sell SignalJun 22, 20264 months ago
MACD: Buy SignalJun 15, 20264 months ago
MACD: Sell SignalJun 1, 20265 months ago
SMA: BearishMay 22, 20265 months ago
SMA: BullishMay 20, 20265 months ago
MACD: Buy SignalMay 20, 20265 months ago
SMA: BearishMay 7, 20265 months ago
MACD: Sell SignalMay 7, 20265 months ago
MACD: Buy SignalMay 6, 20266 months ago
SMA: BullishMay 5, 20266 months ago
MACD: Sell SignalApr 24, 20266 months ago
SMA: BearishApr 20, 20266 months ago
SMA: BullishApr 15, 20266 months ago
MACD: Buy SignalMar 31, 20267 months ago
RSI: OversoldMar 20, 20267 months ago
RSI: OversoldMar 12, 20267 months ago
SMA: BearishFeb 26, 20268 months ago
SMA: BullishFeb 25, 20268 months ago
SMA: BearishFeb 23, 20268 months ago
SMA: BearishFeb 23, 20268 months ago
MACD: Sell SignalFeb 23, 20268 months ago
MACD: Buy SignalFeb 17, 20268 months ago
MACD: Sell SignalFeb 11, 20268 months ago
MACD: Buy SignalJan 27, 20269 months ago
SMA: BullishJan 21, 20269 months ago
SMA: BearishJan 16, 20269 months ago
SMA: BearishJan 15, 20269 months ago
SMA: BullishJan 14, 20269 months ago
SMA: BullishJan 14, 20269 months ago
SMA: BearishJan 13, 20269 months ago
SMA: BearishJan 13, 20269 months ago
MACD: Sell SignalJan 13, 20269 months ago

Key statistics

Market cap
5.79B
Enterprise value
22.28B
Trailing P/E
11.05
Forward P/E
6.39
PEG ratio
0.19
Price / sales
0.78
Price / book
1.86
EPS (TTM)
0.77
Beta
1.14
Dividend yield
1.31%
Payout ratio
37.97%
Profit margin
6.09%
Revenue (TTM)
7.42B
Revenue growth
-0.90%
Free cash flow
572.92M
Total cash
537.00M
Total debt
9.36B
Return on equity
6.93%
Shares outstanding
258.22M
Short % of float
0.00%
50-day average
7.59
200-day average
8.00

Analyst view

Consensus: buy

Buy
Price target (mean) 10.37 +21.8% upside
Target (low)
9.00
Target (mean)
10.37
Target (high)
11.73
Ratings (0m) 2 1 buy · 1 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Nov 2, 2026

Expected Nov 2, 2026. Consensus EPS estimate 0.38576.

Earnings history

Financials — quick view

All financials
GRFS Revenue — annual 7.52B
2010-FY 20102011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
GRFS Net income — annual 402.00M
2010-FY 20102011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
GRFS EPS — annual 0.59
2010-FY 20102011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025

Earnings

GRFS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 2, 2026Sep 30, 20260.3202———
Jul 28, 2026Jun 30, 20260.270.2512-0.02-6.96%
May 7, 2026Mar 31, 20260.16130.1731+0.01+7.32%
Feb 26, 2026Dec 31, 20250.290.28910.00-0.31%
Nov 4, 2025Sep 30, 20250.24170.2108-0.03-12.78%
Jul 29, 2025Jun 30, 20250.230.19-0.04-17.39%

Upgrades / downgrades

GRFS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 26, 2026JP MorganmainNeutralNeutral
Dec 8, 2025JP MorganmainNeutralNeutral
Jun 17, 2025JP MorganmainNeutralNeutral
Mar 12, 2024Deutsche BankdownHoldSell
Dec 5, 2023JP MorganmainNeutralNeutral
Nov 5, 2021Deutsche BankdownBuyHold

About Grifols, S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
Spain
Website
grifols.com

News

Your note

Sign in to keep a note on GRFS — it syncs with the Stock Master app.

Institution ownership

GRFS institution ownership
Holder% heldSharesValueReported
Brandes Investment Partners L.P.14.47%37,816,285321.82MJun 29, 2026
Capital World Investors8.76%22,911,656194.98MJun 29, 2026
Permian Investment Partners, Lp7.55%19,740,679167.99MJun 29, 2026
Black Creek Investment Management Inc.2.94%7,682,05565.37MJun 29, 2026
Bank of America Corporation2.51%6,550,33755.74MJun 29, 2026
Millennium Management Llc1.67%4,369,93437.19MJun 29, 2026

Fund ownership

GRFS fund ownership
Holder% heldSharesValueReported
NEW PERSPECTIVE FUND5.37%14,039,027119.47MSep 29, 2026
Intl Growth & Income Fd.-Intl Growth and Income Fd.1.98%5,180,41644.09MSep 29, 2026
Brandes Investment Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND1.84%4,803,45940.88MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.69%1,812,12615.42MSep 29, 2026
Brandes Investment Trust-BRANDES SMALL CAP VALUE FUND0.63%1,647,43814.02MJun 29, 2026
2023 ETF Series Trust-Brandes International ETF0.34%893,1537.60MJun 29, 2026
Advertisement